Homocysteine Over Genetics: What Poor Methylation Actually Costs

By Michael Rutherford

Functional medicine has spent a decade chasing genetic tests — and MTHFR sits at the center of the obsession. But genetics tell you what's possible, not what's happening. There's a more direct, more honest way to know how a client is actually methylating right now, and to understand what it's costing them downstream: homocysteine.

Genetics Is Potential. Homocysteine Is Reality.

A genetic variant is a predisposition. Carrying an MTHFR 677TT genotype means the enzyme that activates folate runs slower than average — but whether that actually translates into impaired methylation depends entirely on cofactor status, diet, stress, and lifestyle. Plenty of people with the variant methylate perfectly well because their nutrition compensates. Plenty of people with unremarkable genetics methylate poorly because they're depleted. The genotype is a static blueprint; it cannot tell you what the system is doing today.

Homocysteine can. It is the functional output of the methylation cycle — the real-time result of the pathway either keeping up or falling behind. A single homocysteine value integrates the genetic, nutritional, and environmental inputs into one number that reflects current reality.¹ Read in the context of folate and B12, it does something no genetic panel can: it tells you not only that methylation is strained, but where the bottleneck sits and what to do about it. This is why the functional measure should generally come first. The genotype never changes and rarely changes the plan; the homocysteine value changes as you intervene, which makes it the marker you can actually act on and track.

"It's a Methylation Marker" — and Why That Answer Isn't Enough

Ask a functional practitioner what homocysteine tells them and the reply comes quickly: it's a methylation marker. The answer feels like expertise, and it is precisely where most practitioners stop. But "methylation" is a label, not an explanation — and naming a pathway is not the same as understanding what its failure costs.

Methylation is the transfer of a single methyl group from one molecule to another, performed billions of times per second. It switches genes on and off, builds and clears neurotransmitters like serotonin and dopamine, processes hormones for elimination, constructs the phospholipids of cell membranes, and supports the synthesis of glutathione, the body's master antioxidant. It is not a niche pathway. It is one of the most load-bearing processes in human physiology — which means that when it falters, the consequences do not stay local. They cascade.

The Downstream Cascade of Poor Methylation

The most established and best-studied consequence is cardiovascular. Elevated homocysteine is directly toxic to the vascular endothelium: it promotes oxidative stress, impairs nitric oxide signaling, encourages a prothrombotic state, and accelerates atherothrombosis.² Lowering homocysteine with B-vitamin cofactors has been shown to reduce stroke risk.³ This is the relationship most practitioners quietly invert. They treat cardiovascular risk as a separate "heart story" that happens to correlate with homocysteine — when in fact the vascular damage is downstream of the methylation failure the homocysteine is reporting. The heart disease is a symptom of the broken pathway, not a parallel finding.

But the cascade extends well beyond the cardiovascular system, and this is where the depth pays off:

One elevated homocysteine value, read by someone who understands the cascade, opens investigations across every one of these systems. That is the difference between a marker you can name and a marker you can actually use.

Reading It in Context: Folate, B12, and MMA

Once you appreciate the downstream stakes, the next task is finding the bottleneck — and homocysteine doesn't do that alone. Conventional labs flag it only above roughly 15 µmol/L, but the functional optimal sits closer to 5–9 µmol/L, with the lower half of that range more protective. A client at 12 is reassured by a conventional report while their methylation is meaningfully strained.

When homocysteine is elevated, folate and B12 are the essential context, and methylmalonic acid (MMA) resolves which cofactor is involved. MMA accumulates specifically in B12 deficiency — it depends on a separate B12-requiring enzyme — and is unaffected by folate status.⁴

This pairing is especially valuable because serum B12 is a notoriously unreliable marker — a client can show a "normal" serum B12 while being functionally deficient at the tissue level. MMA and homocysteine together catch what serum B12 conceals,⁴ which is exactly the kind of relationship that pattern recognition across markers exists to surface.

The MTHFR Question, Answered Without a Gene Test

Here is where the genetics-versus-function distinction becomes concrete. Suppose homocysteine stays elevated despite folate and B12 that look adequate. That's the scenario where the MTHFR enzyme — and its often-forgotten cofactor, riboflavin — comes into play. Riboflavin is required for MTHFR to produce the active 5-MTHF form of folate, and improving riboflavin status has been shown to lower homocysteine specifically in those with the 677TT genotype.⁵

Notice that you reached this insight by reading the functional pattern, not by ordering a genetic panel first. You identified an MTHFR-relevant bottleneck because homocysteine stayed high in the presence of adequate folate and B12 — and you confirm the approach by re-measuring homocysteine, the live readout that responds to what you do, rather than re-reading a genotype that never moves. There is also a practical trap to avoid: reflexively pushing folate to drive down a high homocysteine can lower the number while masking an underlying B12 deficiency, allowing neurological damage to progress silently.⁶ The cofactor pattern, not the homocysteine value alone, must guide the response.

The Practitioner's Takeaway

Resist the pull toward genotyping as the starting point for methylation. A gene test tells you what's possible; homocysteine tells you what's actually happening, responds to your interventions, and — read in the context of folate, B12, and MMA — points you straight to the bottleneck. Then go further than naming the pathway. Understand that the cardiovascular damage, the cognitive strain, the impaired detoxification, and the mood disruption are downstream consequences of the very methylation failure the marker is reporting. Support the terrain the pattern points to, educate the client, and refer when findings warrant it. Measure the function. Understand the stakes. The number opens the question; the pattern answers it; the genotype was never the point.

Frequently Asked Questions

Do I need an MTHFR genetic test to assess methylation?

Not to understand how a client is methylating right now. A genetic variant indicates a predisposition that may or may not be expressing, while homocysteine reflects actual, real-time methylation function — the integrated result of genetics, nutrient status, and lifestyle. For assessing current status, finding the bottleneck, and tracking response to intervention, the functional marker is more direct and more actionable than a static genotype.

Why isn't calling homocysteine "a methylation marker" enough?

Because naming the pathway doesn't capture what its failure costs. Poor methylation drives cardiovascular damage, cognitive decline, impaired detoxification, and neurotransmitter disruption. A practitioner who understands that cascade reads an elevated homocysteine very differently from one who simply files it under "methylation" — and intervenes more effectively as a result.

What is an optimal homocysteine level?

Conventional labs flag homocysteine only above roughly 15 µmol/L, but a functional optimal sits closer to 5–9 µmol/L, with the lower half of that range generally more protective for cardiovascular and cognitive health. Values in the 10–14 range read as conventionally normal while frequently reflecting genuine methylation strain.

Why read homocysteine with folate, B12, and MMA?

Homocysteine alone signals that methylation is struggling but not why. Folate and B12 are the primary remethylation cofactors, and MMA distinguishes between them — it rises in B12 deficiency but not folate deficiency. Together they convert a single elevated value into a specific, addressable bottleneck, and reveal functional B12 deficiency that a normal serum B12 can hide.

How does the MTHFR variant fit in if I'm not testing for it?

You reach it functionally. If homocysteine stays elevated despite adequate folate and B12, that pattern itself points toward reduced MTHFR activity, where riboflavin — the enzyme's cofactor — becomes relevant. You then confirm by re-measuring homocysteine as you support the terrain, rather than relying on a genotype that never changes and never tells you whether the pathway is currently working.